President Trump’s vaccine executive order has moved from proposal to signed policy, according to Ars Technica, and its most concrete demand is already drawing opposition from the pharmaceutical industry. Axios first reported that the administration was working on an order to reduce the number of childhood vaccinations and split the combined measles, mumps and rubella vaccine, known as MMR, into separate shots. Ars later reported that Trump signed the order on Monday. The order’s stated direction is to reduce childhood vaccinations, but Ars notes that separating MMR would have the opposite mechanical effect for that vaccine. The current MMR shot is administered in two doses. If measles, mumps and rubella were delivered separately, children would receive six shots instead of two for the same three diseases. The implementation problem is larger than scheduling. Ars reports that individual measles, mumps and rubella vaccines are not currently available in the U.S. That means the order would not simply change what pediatricians pull from inventory; it would require manufacturers to develop, test and commercialize separate products. The industry response was unusually fast. Ars reports that PhRMA, the major U.S. pharmaceutical trade group whose members include GSK, Sanofi, Pfizer, Merck, Johnson & Johnson and Novo Nordisk, issued a statement within hours criticizing the order’s approach. PhRMA’s chief medical officer, Michael Ybarra, said prior federal vaccine recommendations were built on extensive scientific research and public-health expertise, and that any changes should meet a comparable evidentiary standard. Ars also reports that Merck and GSK, which make MMR vaccines used in the U.S., pushed back. Citing Stat News, Ars says Merck argued vaccine policy should be grounded in rigorous evidence and said there is no published scientific evidence showing a benefit from separating the MMR combination into three individual shots. GSK similarly pointed to decades of global use and scientific evidence behind its MMR vaccine, according to the Ars summary of Stat’s reporting. Public-health groups have also objected. Ars reports that medical organizations and independent experts criticized the order as unsafe and unscientific, and that the American Academy of Pediatrics called it dangerous. Ars adds that the academy is already involved in litigation over prior changes to federal childhood vaccine recommendations under Trump and Health Secretary Robert F. Kennedy Jr., and that the academy, along with other medical groups, won a temporary injunction reversing most of those changes. The key reported distinction is between a political directive and products that are not currently available in the U.S. Based on the provided reports, the order calls for a change that would require new U.S. vaccine products, while the leading industry group and two relevant manufacturers have questioned the evidence basis for separating MMR into three shots. Who benefits: It is too early to identify a clear commercial beneficiary from the provided reports. The companies named in the reporting — Merck and GSK — are described as pushing back, not positioning for a new market opportunity. Who's exposed: Vaccine manufacturers are exposed to implementation uncertainty if federal recommendations shift. Public-health organizations are also involved in opposing changes to childhood vaccine guidance.